{"preliminary_commentary":{"by_channel":{"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["atezolizumab"]],"indication":"refractory metastatic colorectal cancer","name":"BACCI","nct_id":"NCT02873195","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bacci-nct02873195. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (atezolizumab, bevacizumab, capecitabine)","type":"EXPERIMENTAL"},{"description":"Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (placebo, bevacizumab, capecitabine)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2023-12-01","type":"ACTUAL"},"conditions":["Metastatic Colorectal Carcinoma","Recurrent Colorectal Carcinoma","Refractory Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7"],"enrollment":{"count":133,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG7446","RO5541267","Tecentriq"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF rhuMAb","Avastin","Bevacizumab awwb","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","BP102","BP102 Biosimilar","HD204","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501"],"type":"BIOLOGICAL"},{"name":"Capecitabine","otherNames":["Ro 09-1978/000","Xeloda"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Placebo","otherNames":["placebo therapy","PLCB","sham therapy"],"type":"OTHER"}],"last_update":"2024-08-23","lead_sponsor":"Academic and Community Cancer Research United","official_title":"BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-03-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization to first documentation of disease progression by RECIST v1.1, or death from any cause, assessed up to 20 months"}],"references":[{"citation":"Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040.","pmid":"35179586","type":"DERIVED"}],"start_date":{"date":"2017-07-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT02873195"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bacci-nct02873195"}